ArticleBiochemia medica2026
The analytical impact of extracellular vesicles PSA on different commercial total PSA measurement methods.
Article in Biochemia medica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extracellular vesicles as mediators of prostatic diseases: connecting function to diagnostic and therapeutic applications.Extracellular vesicles and circulating nucleic acids · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Prostate-specific antigen (PSA) can circulate bound to extracellular vesicles (EVs) and its measurement (ev-PSA) can be useful in prostate cancer. Although not designed with that purpose, total PSA assays react with ev-PSA. We evaluated the analytical performance of several total PSA assays in ev-PSA quantification and the impact of ev-PSA on total PSA measurement. Materials and methods: Extracellular vesicles were isolated from 83 serum samples from prostate cancer patients by size exclusion chromatography or ultracentrifugation. PSA was quantified in serum, EVs, International Standard for PSA 17/100 from the World Health Organization (WHO IS 17/100) and exosomes from lymph node carcinoma of the prostate (LNCaP) cell line, using commercial immunoassays (Elecsys, Atellica, Immulite, Liaison and Kryptor). Results: Nanoparticle tracking analysis showed that the WHO IS 17/100 contains significantly less EVs than serum (P < 0.001). The sensitivity to detect ev-PSA followed this order: Elecsys ~ Atellica > Immulite > Liaison > Kryptor. Ev-PSA could be detected in all serum samples with Elecsys and Atellica, but not with Immulite (87.8%), Liaison (58.5%) or Kryptor (48.8%). Bland-Altman analysis showed a proportional bias in ev-PSA quantification between Elecsys and other methods. Addition of ev-PSA to serum samples caused a proportional bias in PSA measurement between Elecsys and Immulite methods, with a relationship (r Conclusions: While ev-PSA can be measured using commercial kits, notable differences exist between methods, which could lead to potential discrepancies in serum total PSA results across various assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.